1-4 of 4
Hans J. Hammers
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K. Choueiri, Laurence Albiges, Michael B. Atkins, Ziad Bakouny, Gennady Bratslavsky, David A. Braun, Naomi B. Haas, John B.A.G. Haanen, A. Ari Hakimi, Michael A.S. Jewett, Eric Jonasch, William G. Kaelin, Jr, Payal Kapur, Chris Labaki, Bryan Lewis, David F. McDermott, Sumanta K. Pal, Kevin Pels, Susan Poteat, Thomas Powles, W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Hans J. Hammers
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 831–839.
https://doi.org/10.1158/1078-0432.CCR-21-3238
Published: 03 March 2022
View article titled, From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Open the PDF for From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit in another window
Journal Articles

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6687–6695.
https://doi.org/10.1158/1078-0432.CCR-21-2283
Published: 15 December 2021
View article titled, Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Open the PDF for Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial in another window
Includes: Supplementary data
Journal Articles

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)

Roberto Pili, David I. Quinn, Hans J. Hammers, Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Ashley Orillion, Dominick Lamonica, Roberto S. Fragomeni, Zsolt Szabo, Alan Hutson, Adrienne Groman, Susan M. Perkins, Richard Piekarz, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23): 7199–7208.
https://doi.org/10.1158/1078-0432.CCR-17-1178
Published: 30 November 2017
View article titled, Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Open the PDF for Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen

Maha Hussain, Paul G. Corn, M. Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Y. Bruce, Susan Moran, Shih-Yuan Lee, H. Mark Lin, Daniel J. George, for the Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (16): 4218–4227.
https://doi.org/10.1158/1078-0432.CCR-14-0356
Published: 13 August 2014
View article titled, Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
Open the PDF for Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen in another window
Includes: Supplementary data